Aim: chronic kidney disease (CKD) is associated with poor outcomes after PCI. We sought to compare different coronary stents used during primary percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI) and CKD. Methods and Results: We selected 2,408 consecutive AMI patients with CKD (eGFR <60mL/min/1.73m2) undergoing primary PCI and divided them into 5 groups based on type of stents implanted – 1) Bare metal stent -BMS 2) Paclitaxel-eluting stent -PES 3) Sirolimus-eluting stent -SES 4) Zotarolimus-eluting stent -ZES and 5) Everolimus-eluting stent -EES. Study end point was 12-month major adverse cardiac events (MACE) which included all-cause death, non-fatal MI, target lesion revascularization (TLR) and target vessel revascularization (TVR). Average number of stents used per vessel was 1.4짹0.7. A total of 292 patients received BMS and 2,116 patients received DES. There was no significant difference in the incidence of 12-month MI, TLR or TVR. All-cause death differed significantly among the groups. The incidence of 12-month MACE in BMS, PES, SES, ZES, and EES was 8.3%, 9.8%, 8.6%, 5.5%, and 2.6% respectively, p <0.001. Stent thrombosis did not differ among the groups. Kaplan Meier analysis did not show any difference for 12-month MACE-free survival among the groups, log-rank p=0.076. It remained same after adjustment for multiple confounders, p=0.356. Conclusion: Any of the 5 commonly used stents is safe to treat AMI patients with CKD undergoing primary PCI. This result is hypothesis-generating and warrants further long-term randomized evaluation.